Platinum Partners
Business Wire Science
CORRECTING and REPLACING Columbia Laboratories Reports Fourth Quarter and Year End 2009 Financial Results
LIVINGSTON, N.J.--(BUSINESS WIRE)--In the table entitled "CONDENSED CONSOLIDATED BALANCE SHEETS," the figure for "Accumulated deficit" under December 31, 2009 should read: (256,979,263) (sted (56,979,263)). The corrected release reads: COLUMBIA LABORATORIES REPORTS FOURTH QUARTER AND YEAR END 2009 FINANCIAL RESULTS Management will host Conference Call at 8:30 AM ET Today Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results of the three- and twelve-months periods ended Dece
Fri, 12 Mar 2010 02:36:00 UT
Akorn, Inc. Enters into an Agreement to Sell Common Stock and Warrants
LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) a niche generic pharmaceutical company, announced today that it has entered into an agreement to issue and sell to Serum Institute of India Ltd. (“Serum”) 1,838,235 shares of the Company’s common stock at $1.36 per share or a 15% discount to the market closing price on March 5, 2010 of $1.60 per share, resulting in aggregate proceeds of $2,500,000. The Company also agreed to issue to Serum a warrant to purchase appr
Thu, 11 Mar 2010 23:31:00 UT
ASBMR Task Force Reviewing Link Between Fractures and Bisphosphonate Therapy
WASHINGTON--(BUSINESS WIRE)--Recent reports suggesting a link between long-term bisphosphonate usage and rare bone fractures have sparked rising concern among patients, health care professionals and the public. The American Society of Bone and Mineral Research (ASBMR) is examining this urgent clinical issue and will present its findings later this year. The ASBMR is a professional, scientific and medical society that brings together clinical and experimental scientists involved in the study of b
Thu, 11 Mar 2010 21:54:00 UT
Santee Education Complex to Participate in Global Debates on Climate Change
LOS ANGELES--(BUSINESS WIRE)--Today, Santee Education Complex announced its participation in the UN Foundation’s Global Debates program, which challenges high school students from around the world to think critically about pressing global issues. This spring they will focus their discussions and actions on the adaptations necessary to combat climate change. With the UN’s completion of climate negotiations last December, it is more important than ever to uphold a global push for inter
Thu, 11 Mar 2010 21:47:00 UT
Bioject to Report Fourth Quarter and Year-End 2009 Financial Results
PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OTCBB: BJCT), a leading developer of needle-free injection therapy systems, announced today that the Company will report its financial results for the fourth quarter and full year ended December 31, 2009 on Wednesday, March 17, 2010, after the close of the financial markets. Management will conduct a conference call on Thursday, March 18, 2010 at 10:00 a.m. Eastern Time to review the results for the quarter and the year. Ralph M
Thu, 11 Mar 2010 21:30:00 UT
New Q & A Research Survey Shows Toyota Image Hard Hit by Recent Recall
NOVATO, Calif.--(BUSINESS WIRE)--New Q & A Research Survey Shows Toyota Image Hard Hit by Recent Recall Many Americans Now More Likely to Buy American
Thu, 11 Mar 2010 20:53:00 UT
Therapy Guidance for Patients with Colorectal Cancer Discussed at NCCN Annual Conference
HOLLYWOOD, Fla.--(BUSINESS WIRE)--Highlights of the latest version of the NCCN Guidelines for Colon and Rectal Cancer were presented at the NCCN Annual Conference by Paul F. Engstrom, MD, of Fox Chase Cancer Center.
Thu, 11 Mar 2010 19:54:00 UT
Agios Pharmaceuticals Appoints William Kaelin Jr., M.D. to Scientific Advisory Board
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced the appointment of William Kaelin Jr., M.D., to its scientific advisory board. Dr. Kaelin currently serves as a Professor of Medicine at Harvard Medical School. Dr. Kaelin’s laboratory focuses on tumor suppressor genes and the normal functions of the proteins they encode. “
Thu, 11 Mar 2010 18:00:00 UT
LifeSciences BC Announces Recipients of the 2010 LifeSciences British Columbia Awards
VANCOUVER, British Columbia--(BUSINESS WIRE)--LifeSciences British Columbia today announced the recipients of the 2010 LifeSciences British Columbia Awards. They are: Genome BC Award for Scientific Excellence: - Drs. Marco Marra, Rob Holt, and Steven Jones – Michael Smith Genome Sciences Centre Innovation & Achievement: - Dr. Andy Hoffer – Lungpacer Medical Leadership Award: - Mr. Don Avison Medical Device Company of the Year: - Neoteric Life Sciences Company of the Year: - Cardi
Thu, 11 Mar 2010 17:05:00 UT
Blue Spoon Consulting Publishes New Industry Ecosystem to Change the Effect of Asthma Worldwide
NEW YORK--(BUSINESS WIRE)--Blue Spoon Consulting Group, LLC, today published its design for an industry ecosystem to change the effect of asthma worldwide. Available for download through the Blue Spoon Consulting website (www.bluespoonconsulting.com), the ecosystem makes novel linkages between industry players to create new health and economic value. The strategy innovation is centered on designing systemic collaboration around shared marketspace, unifying stakeholders to simultaneously grow bus
Thu, 11 Mar 2010 14:30:00 UT
Imaging Diagnostic Systems Exhibits at the 2010 European College of Radiology Conference
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--IMDS showcased its CT Laser Mammography system at European College of Radiology
Thu, 11 Mar 2010 14:30:00 UT
Nutra Pharma to Exhibit at the 12th IDGA Battlefield Healthcare Summit in Washington, D.C.
CORAL SPRINGS, Fla.--(BUSINESS WIRE)--Nutra Pharma will be exhibiting its over-the-counter (OTC) and prescription pain relievers, Nyloxin OTC and Nyloxin Rx, at the 12th IDGA Battlefield Healthcare Summit.
Thu, 11 Mar 2010 14:25:00 UT
Smart Software Awarded Second National Science Foundation Innovation Research Grant
BELMONT, Mass.--(BUSINESS WIRE)--Smart Software, Inc., provider of industry-leading demand forecasting, planning, and inventory optimization solutions, today announced that it has been awarded a second Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). Nationally, only 20% of the NSF grant applicants were funded. Smart will use the research funds to extend and improve its current intermittent demand forecasting solution by developing an advanced p
Thu, 11 Mar 2010 14:00:00 UT
SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE ROTH 22ND ANNUAL OC GROWTH STOCK CONFERENCE
SAN DIEGO--(BUSINESS WIRE)--Senomyx to present at ROTH Conference on 3-16-10 at 3:30pm EST; audio at IR tab on www.senomyx.com.
Thu, 11 Mar 2010 13:30:00 UT
BioSante Announces Positive Leukemia Vaccine Results
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate). All patients enrolled in the trial used Gleevec for at least one year and still had cancer cells present. The study was conducted by researchers at the Johns
Thu, 11 Mar 2010 12:55:00 UT
Geoff Cole of Brain Training Centers of Florida Earns Masters Level II Certification
MIAMI--(BUSINESS WIRE)--Geoff Cole of the Brain Training Centers of Florida (BTC) has earned the Masters Level II Certification . He now is the only Master level or higher certified brain trainer in Florida.
Thu, 11 Mar 2010 12:05:00 UT
Seattle Genetics Expands Antibody-Drug Conjugate Patent Portfolio
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics’ ADC programs, most notably brentuximab vedotin (SGN-35), as well as many ADC programs in development by its collaborators. Brentuximab vedotin, an ADC that utilizes
Thu, 11 Mar 2010 12:00:00 UT
Safeguard Scientifics Announces Fourth Quarter and Year-End 2009 Financial Results
WAYNE, Pa.--(BUSINESS WIRE)--Safeguard Scientifics Announces Fourth Quarter and Year-End 2009 Financial Results
Thu, 11 Mar 2010 11:00:00 UT
Precision BioSciences Announces that the European Patent Office Issues Written Decision Confirming Cellectis’ Loss of Patent Protection for Single-Chain Meganucleases in Europe
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., today announced that the Opposition Division of the European Patent Office (EPO) has issued a written decision confirming its November 18, 2009 revocation of the previously granted claims of Cellectis’ European Patent No. 1 485 475. As previously reported, after an oral hearing in an Opposition Proceeding initiated by Precision BioSciences, Cellectis’ previously granted claims to single-chain meganucleases, i
Thu, 11 Mar 2010 09:00:00 UT